Furthermore, PRDX5 also predicted poor PFS for all ovarian cancer patients, endometrioid ovarian cancer patients, grade II ovarian cancer patients, and stages III and IV ovarian cancer patients. Here, PRDX5 is linked to ovarian cancer.